Brokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Target Price at $9.80

Cardiff Oncology, Inc. (NASDAQ:CRDF) has been given an average rating of “Hold” by the six ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $7.50.

Several equities research analysts have weighed in on CRDF shares. TD Cowen downgraded shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research note on Monday, June 1st. Craig Hallum cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Monday, May 18th. HC Wainwright lowered Cardiff Oncology from a “buy” rating to a “neutral” rating in a research report on Monday, June 1st. Finally, Wall Street Zen downgraded Cardiff Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th.

Cardiff Oncology Stock Performance

Cardiff Oncology stock opened at $1.32 on Friday. The stock has a market capitalization of $90.25 million, a price-to-earnings ratio of -1.97 and a beta of 1.44. Cardiff Oncology has a 52-week low of $1.16 and a 52-week high of $4.55. The stock’s 50 day moving average price is $1.51 and its two-hundred day moving average price is $1.87.

Cardiff Oncology (NASDAQ:CRDF) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.09 million. Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%. On average, equities research analysts forecast that Cardiff Oncology will post -0.66 EPS for the current year.

Insider Activity at Cardiff Oncology

In other news, CEO Mani Mohindru bought 24,703 shares of the stock in a transaction dated Thursday, June 18th. The shares were bought at an average cost of $1.21 per share, with a total value of $29,890.63. Following the completion of the transaction, the chief executive officer directly owned 24,703 shares of the company’s stock, valued at $29,890.63. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Gary W. Pace bought 30,000 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The stock was purchased at an average price of $1.22 per share, for a total transaction of $36,600.00. Following the completion of the acquisition, the director owned 1,356,376 shares in the company, valued at $1,654,778.72. This represents a 2.26% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 8.50% of the company’s stock.

Institutional Investors Weigh In On Cardiff Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in CRDF. Brooklyn Investment Group acquired a new stake in shares of Cardiff Oncology in the 3rd quarter worth about $26,000. Capital Advisors Wealth Management LLC acquired a new position in Cardiff Oncology during the 4th quarter valued at about $30,000. Tamar Securities LLC acquired a new position in Cardiff Oncology during the 4th quarter valued at about $32,000. R Squared Ltd bought a new stake in Cardiff Oncology during the 4th quarter worth approximately $36,000. Finally, Engineers Gate Manager LP bought a new stake in Cardiff Oncology during the 2nd quarter worth approximately $43,000. 16.29% of the stock is owned by institutional investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.